Xencor in Research and License Agreement with Roche's Genentech

Date : 02/05/2019 @ 6:29PM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 38.23  0.06 (0.16%) @ 9:00PM

Xencor in Research and License Agreement with Roche's Genentech

Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Xencor Charts.

By Michael Dabaie


Xencor Inc. (XNCR) said Tuesday it has entered a research and license agreement with Genentech, part of Roche (RHHBY).

Genentech will pay Xencor $120 million upfront, and Xencor will be eligible to receive up to $180 million in development milestones per program and profit share from commercialized medicines.

The deal aims to develop and commercialize novel IL-15 cytokine therapeutics.

"We believe cytokine therapy will play an important role in the treatment of a wide range of diseases, including cancer," said James Sabry, global head of pharma partnering for Roche.

Xencor shares were recently up 4% to $37.88.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

February 05, 2019 13:14 ET (18:14 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.